Neural Connectivity During Therapy for Adolescent PTSD

Sponsor
The University of Texas Health Science Center at San Antonio (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05423444
Collaborator
(none)
180
2
51.9

Study Details

Study Description

Brief Summary

Posttraumatic stress disorder in adolescence impairs neurobiological networks underlying cognitive, social and emotional skills. Neuroimaging research that seeks to identify the neural mechanisms of treatments for PTSD could lead to novel treatments, but progress has been slow using current methods. The proposed study uses an innovative approach to identify neural mechanisms of specific phases of trauma-focused therapy for youth with PTSD, allowing a new understanding of brain changes associated with the process of therapy.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: TF-CBT
  • Behavioral: TAU
N/A

Detailed Description

Posttraumatic stress disorder (PTSD) during adolescence negatively impacts brain networks underlying cognitive, social, and emotional function. Early intervention is important for mitigating long-term effects, but about 20% of youth do not improve sufficiently with current approaches. By identifying the neurobiological mechanisms of effective therapies, the investigators facilitate the development of novel or personalized treatment approaches for youth with PTSD. However, there has been limited progress in identifying the neural mechanisms of treatment using neuroimaging, partly because most studies collect neuroimaging data at only baseline and end-of-treatment, which collapses across multiple parts of the therapeutic process. The objective of the proposed study is to take a new approach by identifying neural mechanisms associated with specific phases of trauma therapy for youth with PTSD. The central hypothesis is that each phase produces specific brain changes that reflect the acquisition of skills and experiences occurring during that phase. Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) is evidence-based and widely-used to treat children and adolescents with PTSD. It consists of 3 well-defined phases, providing an opportunity to test hypotheses with neuroimaging: changes in executive control networks will occur during the skills phase, changes in limbic networks during the narrative phase, and changes in default mode networks during the consolidation phase. To test these hypotheses, the investigators will recruit N=180 girls and boys, ages 12-17, who have PTSD following interpersonal trauma, such as physical abuse, sexual abuse, or witnessing violence. A randomized controlled trial design will be used to assign participants to either Trauma-focused Cognitive Behavioral Therapy (TF-CBT; provided by study team clinicians who meet fidelity standards) or Treatment as Usual (TAU; provided in the community and does not follow a phased structure). Functional magnetic resonance imaging (fMRI) data will be collected before and after each of the 3 phases of TF-CBT or the same time intervals of TAU. Individual differences in age, sex, dissociative subtype, symptom severity and other variables will be investigated as covariates of phase-related neural changes. Analyses will identify the phases of TF-CBT for which brain regions and networks change for the TF-CBT but not the TAU group. The phase(s) that best predict end-of-treatment symptom improvement also will be identified. Exploratory analyses will use neuroanatomical and white matter diffusivity scans to identify co-occurring changes in brain structure. The proposed innovative study will provide novel information on the neurobiological and cognitive mechanisms associated with the process of trauma therapy for youth with PTSD.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
180 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized controlled trial of Trauma-focused Cognitive Behavioral Therapy (TF-CBT) versus Treatment as Usual (TAU)Randomized controlled trial of Trauma-focused Cognitive Behavioral Therapy (TF-CBT) versus Treatment as Usual (TAU)
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
An independent assessor will conduct interviews to quantify symptom severity during and after treatment. The participant will not be given specific information about treatment assignment or the differences between the two treatments.
Primary Purpose:
Basic Science
Official Title:
Neural Connectivity Before and After Each of the Three Treatment Phases of Trauma-focused Therapy for Adolescent Posttraumatic Stress
Anticipated Study Start Date :
Nov 1, 2022
Anticipated Primary Completion Date :
Feb 1, 2027
Anticipated Study Completion Date :
Feb 28, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Trauma-focused cognitive behavioral therapy (TF-CBT)

Trauma-focused Cognitive Behavioral Therapy (TF-CBT) is an evidence-based psychotherapy that is considered the gold-standard treatment for trauma in youth. The TF-CBT model is flexible but it follows a specific order of phases and components, including psychoeducation, emotion regulation skills, processing the trauma narrative, and safety planning. Sessions are provided weekly for 18-weeks.

Behavioral: TF-CBT
evidence-based psychotherapy for trauma in youth

Active Comparator: Treatment As Usual (TAU)

Treatment as usual (TAU) consists of the standard-of-care psychotherapy as provided by licensed clinicians at a local clinic. The order and choice of techniques is based on the knowledge and preferences of the clinicians. Sessions are provided weekly for 18-weeks.

Behavioral: TAU
treatment as usual

Outcome Measures

Primary Outcome Measures

  1. Mean intensity within functional connectivity map of intrinsic network [week 0 (baseline)]

    functional MRI scans will be used to assess neural connectivity

  2. Mean intensity within functional connectivity map of intrinsic network [week 6]

    functional MRI scans will be used to assess neural connectivity

  3. Mean intensity within functional connectivity map of intrinsic network [week 12]

    functional MRI scans will be used to assess neural connectivity

  4. Mean intensity within functional connectivity map of intrinsic network [week 18]

    functional MRI scans will be used to assess neural connectivity

Eligibility Criteria

Criteria

Ages Eligible for Study:
12 Years to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ages 12-17 and Tanner stage 2 or above

  • history of interpersonal trauma

  • PTSD symptoms with a rating of '2' or higher on at least one symptom from each of the 4 clusters, using the Clinician-Administered PTSD Scale for Children and Adolescents, and having a duration of at least one month

Exclusion Criteria:
  • current or past use of psychiatric medications

  • severe suicidal/homicidal ideation

  • current hospitalization

  • other current psychotherapy or previous treatment with TF-CBT

  • history of head injury with loss of consciousness for >5 minutes

  • IQ<85

  • major medical illness

  • MRI contraindications (metal in body; braces on teeth)

  • psychosis, bipolar 1, autism, developmental disorder, panic disorder

  • first-degree family member with diagnosis of psychosis or bipolar I disorder

  • substance dependence within the past 3 months or current drug use that is frequent

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • The University of Texas Health Science Center at San Antonio

Investigators

  • Principal Investigator: Amy Garrett, PhD, University of Texas Health Science Center San Antonio

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Amy Garrett, Assistant Professor, The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier:
NCT05423444
Other Study ID Numbers:
  • 171195
First Posted:
Jun 21, 2022
Last Update Posted:
Jun 21, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Amy Garrett, Assistant Professor, The University of Texas Health Science Center at San Antonio
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 21, 2022